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Background: Dose intense chemotherapy may improve efficacy with acceptable toxicity. A phase II study was
conducted to determine the feasibility of a dose-intense two weekly schedule of capecitabine, oxaliplatin, and
bevacizumab in metastatic colorectal cancer (mCRC).
Methods: 49 patients with previously untreated mCRC were recruited. Nineteen received capecitabine (1750
mg/m2 oral BD days 1–7)oxaliplatin (85 mg/m2i.v. day 1) and bevacizumab (5 mg/kg i.v. day 1) using a 14-day cycle
(C1750). Following toxicity concerns capecitabine was reduced to 1500 mg/m2oral BD (C1500) and 30 further
patients recruited.
Results: Over 80% of patients received at least 75% of planned chemotherapy doses over the first two cycles. At
C1750 Grade 3 or higher toxicity occurred in 74% (95% CI 49% to 91%) and on C1500 in 70% (95% CI 51% to 85%).
The median progression-free survival was 6.9 months (95% CI 4.7 to 8.7) for C1750 dose and 8.9 months (95% CI 4.1
to 12.4) for C1500. 3 treatment-related deaths occurred.
Conclusions: Dose intense capecitabine and oxaliplatin with bevacizumab does not show additional efficacy and
has potentially significant toxicity. Its use outside of clinical trials is not recommended.
Trial registration: ISRCTN41540878
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Colorectal cancer (CRC) is the second most incident solid
tumour and the second leading cause of cancer-related
death worldwide with over 1.2 million new cancer cases
and 608,700 deaths estimated to have occurred in 2008
[1]. Due to an increasing incidence in developing coun-
tries as well as an aging population structure, the burden
of colorectal cancer will continue to rise despite reduc-
tions in mortality in western countries [2]. With the use of
chemotherapy and targeted agents for stage 4 disease, me-
dian overall survival has increased from 6 months with* Correspondence: mp.findlay@auckland.ac.nz
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reproduction in any medium, provided the orsupportive care alone to over 20 months. The monoclonal
antibody against vascular endothelial growth factor, beva-
cizumab (Avastin, Roche), improved progression-free and
over-all survival when combined with IFL chemotherapy
[3], and increased progression-free survival with a non-
statistically significant increase in overall survival when
combined with oxaliplatin based chemotherapy [4] and
has been widely adapted as a standard component of first
line therapy.
Capecitabine is an oral pro-drug of 5-fluorouracil,
which in combination with Oxaliplatin (CapOx) has simi-
lar efficacy to the reference regimen FOLFOX-4, and
obviates the need for a central venous access device and
so is more convenient. Studies comparing CapOx in com-
bination with bevacizumab have demonstrated similarl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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However up to 20% of patients receiving CapOx experi-
enced grade 3/4 diarrhoea [5-8] hence toxicity improve-
ments in this schedule that maintain or improve efficacy
are required.
The standard CapOx regimen is given on a 21-day
cycle, with oxaliplatin 130 mg/m2iv on Day 1 and cape-
citabine 1000 mg/m2 PO BD on days 1–14. Mathemat-
ical modelling as well as pre-clinical studies in breast
cancer mouse xenografts have indicated that a dose-dense
regimen of 7 days treatment with capecitabine followed by
7 days rest may result in a higher maximum tolerated dose
being achieved [9]. Other groups have investigated the use
of dose-dense capecitabine with oxaliplatin [10], adopting
a two-weekly cycle with oxaliplatin 85 mg/m2 on Day 1,
and a 7 day administration of capecitabine. In a dose es-
calation study using this 7/7 schedule, a maximum toler-
ated dose of capecitabine was reached at 1750 mg/m2 PO
BDd1-7. The effective daily dose of capecitabine in a
21 day schedule is 1333 mg/m2/day, whereas in the 14 day
schedule using 1750 mg/m2 the daily dose received of cap-
ecitabine is 1750/m2/day – a 30% increase in total capecit-
abine delivered.
In the follow-on phase II trial [11] 89 patients were
randomised to receive either dose-intense CapOx or a
standard 21 day regimen. Those allocated to the dose in-
tense arm had a significantly longer median progression-
free survival time than those in the control arm (10.5 v
6.0 months; HR 2.15: 95% CI 1.43 to 4.35; p = 0.0013). In
addition, there were comparable rates of haematological
and non-haematological toxicities, and only 12% Grade
3/4 diarrhoea observed in the dose-dense arm.
Given that the addition of bevacizumab to chemotherapy
appears to improve PFS, and that dose-dense chemother-
apy may improve efficacy, we considered that dose-intense
CapOx with bevacizumab warranted exploration. We
undertook a phase II study to determine the feasibility
and safety of a dose-intense capecitabine and oxaliplatin
schedule with bevacizumab for patients with previously
untreated advanced colorectal cancer.
Methods
This national, multicentre, open-label, single arm, phase II
clinical trial had the primary objective of determining
the feasibility and safety of a dose-dense Capecitabine-
Oxaliplatin-Bevacizumab regimen. Feasibility was deter-
mined by dose delivery, measured by the proportion of
patients who received at least 75% of the planned dose for
the first two cycles. Safety was measured according to
Common Toxicity Criteria for Adverse Events v3.0. Sec-
ondary end-points included radiologic response rate, pro-
gression free survival and overall survival. The trial was
approved by the Multi-Region Ethics Committee (MEC/
06/04/041). The study was registered as ISRCTN41540878.Patient selection
Patients were eligible if aged 18 years of age or older
with previously untreated, histologically or cytologic-
ally confirmed locally recurrent or metastatic colorec-
tal adenocarcinoma, ECOG performance status of 0
or 1, absolute neutrophil count of ≥1.5×109/L, platelet
count of ≥75×109/L, serum total bilirubin <30 umol/L,
negative urinary protein on dipstick testing or <1 g/
24 hour collection, and creatinine clearance ≥ 50 mL/min
by Cockcroft Gault calculation or direct measurement in
accordance with local practice. All patients provided writ-
ten informed consent. Prior adjuvant therapy was allowed
if completed more than 6 months prior to enrollment. Ex-
clusion criteria included prior chemotherapy for advanced
CRC, tumour invasion of major blood vessels, recent
major surgery, clinically significant cerebrovascular or
cardiovascular disease including uncontrolled hyperten-
sion, congenital or acquired coagulopathy or full anti-
coagulation prior to registration. Patients were enrolled
from all 6 New Zealand Cancer Centres.
Treatment
Patients received capecitabine 1750 mg/m2 PO BD days
1–7, oxaliplatin 85 mg/m2 i.v. day 1 and bevacizumab
5 m/kg i.v. day 1 of a 14 day cycle (C1750). After an in-
terim safety analysis the capecitabine dose was reduced
to 1500 mg/m2 PO BD d1-7 (C1500) with doses of the
other agents unchanged. Treatment was continued until
disease progression, unacceptable toxicity or patient de-
cision. All patients were followed for adverse events
until 31st May 2008 and until 1 July 2009 for survival.
Statistical considerations
Dose delivery was assessed as the proportion of patients
who received at least 75% of the planned chemotherapy
dose over the first two cycles. Dose intensity for each pa-
tient was calculated as the average proportion of the per
protocol dose given per day while still on study chemo-
therapy over the first two cycles. Toxicity was graded
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events v 3.0 (NCI-
CTCAE v3.0). Progression-free survival was calculated
from day 1 of treatment until first documented evidence
of disease progression or death from any cause. Modified
RECIST 1.0 criteria were used to determine the tumour
response, with confirmatory scans at 8 weeks (as opposed
to 4) to reduce the burden of investigational procedures
for the patients. For key outcome measures 95% confi-
dence intervals are reported for estimates of proportions.
The Kaplan-Meier product limit estimator [12] was used
to estimate progression free survival and overall survival.
Median survival was reported, with confidence intervals
calculated using the method of Brookemeyer and Crowley
[13] with log transform. All analyses were stratified by
Table 1 Patient demographic and disease characteristics
Total C1750 mg/m2 C1500 mg/m2
n = 49 n = 19 n = 30
Age at registration,
median (IQ range)
63 (55, 67) 64 (52, 68) 62 (55, 65)
Gender, n (%)
Female 31 (63.3) 11 (57.9) 20 (66.7)
Male 18 (36.7) 8 (42.1) 10 (33.3)
Ethnicity, n (%)
European 47 (96.0) 18 (94.7) 29 (96.7)
Maori 1 (2.0) 1 (5.3) 0 (0.0)
Other 1 (2.0) 0 (0.0) 1 (3.3)
Histology, n (%)
Adenocarcinoma - NOS 20 (40.8) 7 (36.8) 13 (43.3)
Adenocarcinoma - poorly
differentiated
4 (8.2) 2 (10.5) 2 (6.7)
Adenocarcinoma -
moderately differentiated
17 (34.7) 9 (47.4) 8 (26.7)
Adenocarcinoma - well
differentiated
1 (2.0) 1 (5.3) 0 (0.0)
Mucinious 7 (14.3) 0 (0.0) 7 (23.3)
Disease Status, n (%)
Distant metastases only 41 (83.7) 17 (89.5) 24 (80.0)
Local recurrence 5 (10.2) 2 (10.5) 3 (10.0)
Distant metastases and
local recurrence





11 (22.4) 5 (26.3) 6 (20.0)
Radiotherapy 8 (16.3) 3 (15.8) 5 (16.7)
Surgery 44 (89.8) 17 (89.5) 27 (90.0)
WHO Performance
Status, n (%)
0 42 (85.7) 18 (94.7) 24 (80.0)
1 7 (14.3) 1 (5.3) 6 (20.0)
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was chosen to allow a precision of ± 0.09 for a 95% confi-
dence interval around an observed proportion of 0.8.
Results
Patient characteristics
Between June 2006 and June 2007, 49 patients were
recruited. Characteristics are summarized in Table 1.
Nineteen patients received capecitabine at 1750 mg/m2
(C1750 group). An interim safety analysis was planned
after 20 patients were recruited but was conducted after
19 patients due to investigator concerns about gastro-
intestinal toxicity. This resulted in a dose reduction in
capecitabine to 1500 mg/m2/BD (C1500 group), which
was then received by 30 patients. Following 2 further
deaths at this dose level, the study was terminated. The
median follow-up was 23 months for the C1750 group
and 15 months for the C1500 group.
Dose delivery of chemotherapy
Over 80% of patients received at least 75% of the planned
dose of all three drugs in both dose groups (Table 2). The
median dose-intensity for each drug over all cycles re-
ceived was 0.8 for the C1750 group and was 0.96-1.0 in
the C1500 group. Median number of cycles received was
7 for C1750 and 8 for C1500 (Figure 1, Table 2). The prin-
cipal reasons for early discontinuation were gastrointes-
tinal adverse events, fatigue, or pain. At the lower dose
level, 15/30 patients discontinued treatment prior to pro-
gression. The main adverse events in this group were
gastrointestinal, infection, sensory neuropathy and fatigue.
Safety
Among the 19 patients on C1750, 14 patients developed
a grade 3 or greater toxicity (74%; 95% CI 49-91%); at
C1500 grade 3/4 toxicity occurred in 21 of 30 patients
(70%; 95% CI 51-85%) (Table 3). The most common tox-
icities at both dose levels were hand-foot syndrome,
diarrhoea and nausea and vomiting. There were three
treatment related deaths: one in the C1750 group due to
an oesophageal perforation following chemotherapy in-
duced emesis; two occurred in the C1500 group, with
one patient developing fulminant diarrhea and subsequent
sepsis 7 days after commencement of therapy, suggestive
of DPD deficiency, and the other due to bowel perforation
and sepsis in a patient with an unresected rectal primary.
Following the third treatment-related death, the study was
closed.
Efficacy
Forty-three patients were evaluable for response (Table 4),
with two confirmed complete responses, and 20 partial
responses (13 confirmed at 8 weeks). Of the seven un-
confirmed responses, new lesions were found at theconfirmatory scan in three patients, one patient died,
and the remaining three stopped treatment so no con-
firmatory scan was carried out. The response rates (con-
firmed) were 47.1% (95% CI 23.0-72.2%) for C1750 and
26.9% (95% CI 11.6-47.8) for C1500.
The median progression free and overall survival
(Figures 2 and 3) for C1750 was 6.9 months (95% CI 5.9
to 10.3) and 19.9 months (95% CI 11.9-26.3), and for the
C1500 group was 8.4 months (95% CI 5.2 to 12.4) and
15.9 months (95% CI 13.1-27.7).
Discussion and conclusions
Combination chemotherapy with capecitabine is a con-
venient alternative to infusional regimens with preserved





n = 49 n = 19 n = 30
Reason for discontinuation
of chemotherapy, n (%)
Progression 12 (24.5) 4 (21.1) 8 (26.7)
Need for surgery 6 (12.2) 2 (10.5) 4 (13.3)
Death (treatment-related
cause)
3 (6.1) 1 (5.3) 2 (6.7)




11 (22.4) 7 (36.8) 4 (13.3)
Still on treatment 1 (2.0) 0 (0.0) 1 (3.3)
Receipt ofat least 75%
of planned dose in first
two cycles, n (%)
Each drug separately
Capecitabine 42 (85.7) 18 (94.7) 24 (80.0)
Oxaliplatin 46 (93.9) 19 (100.0) 27 (90.0)
Bevacizumab 44 (89.8) 17 (89.5) 27 (90.0)




Capecitabine 0.95 (0.66, 1) 0.8(0.57,1) 0.96 (0.67,1)
Oxaliplatin 1 (0.8, 1) 0.8 (0.67,1) 1 (1,1)
Bevacizumab 1 (0.8, 1) 0.8 (0.67,1) 1 (1,1)
Figure 1 Number of cycles of chemotherapy completed. The
median number of cycles completed was 8 (IQ range (5,12)) on dose
C1750mg/m2 and 7 (IQ range (5,13)) on C1500 mg/m2.
Table 3 Numbers of patients experiencing a grade 3 or




C1750 mg/m2 C1500 mg/m2
n = 19 n = 30
Hand-foot skin reaction
(≥grade 2)
14 (28.6) 6 (31.6) 8 (26.7)
Diarrhoea 13 (26.5) 6 (31.6) 7 (23.3)
Nausea and vomiting 9 (18.4) 4 (21.1) 5 (16.7)
Pain – abdomen 4 (8.2) 2 (10.5) 2 (6.7)
Perforation 4 (8.2) 3 (15.8) 1 (3.3)
Obstruction 2 (4.1) 0 (0.0) 2 (6.7)
Sensory neuropathy 5 (10.2) 2 (10.5) 3 (10.0)
Fatigue 4 (8.2) 2 (10.5) 2 (6.7)
Thrombosis/thrombus/
embolism
4 (8.2) 2 (10.5) 2 (6.7)
Hypokalemia 4 (8.2) 2 (10.5) 2 (6.7)
Infection – sepsis 3 (6.1) 0 (0.0) 3 (10.0)
Febrile neutropenia 2 (4.1) 1 (5.3) 1 (3.3)
ALT 1 (2.0) 1 (5.3) 0 (0.0)
Hypertension 0 (0.0) 0 (0.0) 0 (0.0)
Acute respiratory distress
syndrome
1 (2.0) 0 (0.0) 1 (3.3)
Any grade 3 or higher
adverse event
35 (71.4) 14 (73.8) 21 (70.0)
95% confidence interval (56.7, 83.4) (48.8, 90.9) 50.6, 85.3)
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in greater dose delivery and enhanced efficacy over
21 day schedules. At the time of study inception, we
were not aware of any published reports of a dose-
intense capecitabine-oxaliplatin schedule combined
with bevacizumab.
Norton-Simon mathematical and pre-clinical models
of capecitabine administration in breast cancer mouse
xenografts have indicated that a 7 day treatment schedule
followed by a seven day rest (7/7 schedule) may result in a
higher maximum tolerated dose of capecitabine being
achieved, with lower toxicity [9]. A phase 1 trial of capecit-
abine monotherapy in breast cancer found this 7/7 sched-
ule was well tolerated with 1/21 patients experiencing
grade 3 diarrhoea [14]. A subsequent phase 2 study of
fixed-dose capecitabine 2000 mg/PO/BD 7/7 combined
with bevacizumab 10 mg/kg q14d had activity and re-
ported 0% grade 3/4 diarrhoea [15]. A randomised phase
2 study containing 89 patients compared standard CapOx
(Cap1000 mg/m2/BD d1-14 q21d; Ox130 mg/m2 d1
q21d) with dose intense CapOx (Cap 1750 mg/m2/BD
d1-7, Ox85 mg/m2/d1; q14d) and reported a higher con-
firmed radiological response rate (54.5% v 42.2%) and lon-
ger PFS (10.5 v 6.0 months, p = 0.0013) favouring the dose
intense schedule. Grade 3/4 diarrhoea rates were reported
Figure 2 Kaplan-Meier estimates of progression free survival.
The median progression-free survival was 6.9 months (95% CI (5.9,
10.3)) in the capecitabine 1750 mg/m2 group and 8.4 months (95%
CI(5.2, 12.4)) in the capecitabine 1500 mg/m2 group.
Figure 3 Kaplan-Meier estimates of overall survival. The median
survival was 19.9 months (95% CI (11.9, 26.2)) in the Capecitabine
1750 mg/m2 group and 15.9 months (95% CI (13.1, 27.7)) in the
capecitabine 1500 mg/m2 group.





n = 49 n = 19 n = 30
Patient status at end of
follow-up, n (%)
Alive, without disease progression 9 (18.4) 1 (5.3) 8 (26.7)
Alive with disease progression 19 (38.8) 9 (47.4) 10 (33.3)
Death after disease progression 15 (30.6) 6 (31.6) 9 (30.0)
Death without disease progression 6 (12.2) 3 (15.8) 3 (10.0)
Non measurable disease, n 6 2 4
Best overall response, n (%) n = 43 n = 17 n = 26
Complete response 2 (4.7) 1 (5.9) 1 (3.9)
Partial response 20 (46.5) 8 (47.1) 12 (46.2)
Stable disease 15 (34.9) 8 (47.1) 7 (26.9)
Progressive disease 5 (11.6) 0 (0.0%) 5 (19.2)
Died 1 (2.3) 0 (0.0%) 1 (3.9)








Confirmed response, n (%) n = 43 n = 17 n = 26
Complete response 2 (4.7) 1 (5.9) 1 (3.9)
Partial response 13 (30.2) 7 (41.2) 6 (23.1)
Stable disease 8 (18.6) 2 (11.8) 6 (23.1)
Progressive disease 15 (34.9) 5 (29.4) 10 (38.5)
Died 5 (11.6) 2 (11.8) 3 (11.5)
Confirmed complete or partial
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spectively [11]. Reported rates of grade 3/4 diarrhoea of
have been reported with three weekly CapOx-B regimens
[16]. This contrasts with the results of a randomised phase
3 study, published following the completion of our study,
of 435 patients of patients with advanced colorectal can-
cer, comparing 21 day Capecitabine with Oxaliplatin
(Capecitabine 850 mg/m2/BD d1-14 q21d; Oxaliplatin
130 mg/m2 IV d1 q21d) to a 14 day schedule with in-
creased dose capecitabine (Cap 1500 mg/m2/BD d1-7
q14d,Oxaliplatin 85 mg/m2 IV d1 q14d). This study
showed the dose-intense regimen had a non-significantly
shorter PFS compared to the standard regimen (8.4 months
v 9.7 months; hazard ratio [HR] = 0.84; 95% CI = 0.62-
1.13). Patients in the dose intense group experienced
higher rates of grade 3/4 diarrhoea (29% vs 24%), hand-
foot syndrome (12% vs 8%), and treatment discontinuation
rates (40% vs 20%) [17]. A summary of studies of dose-
intense regimens is described in Table 5.
Our study tested a dose of Capecitabine at the upper
range of doses previously tested, with the addition of
bevacizumab. Our observed rate of 23% G3/4 diarrhoea
is comparable to other studies of Capecitabine-based dou-
blets. Indeed our overall grade 3/4 adverse event rate of
74% is comparable to the 80% grade 3/4 adverse event rate
for FOLFOX4/CapOx-Bev arms seen in the NO16966
study [6]. However the 3 deaths represented unacceptably
high toxicity, and we observed more perforations than
seen in the NO16966 study. The overwhelming diarrhoea
that resulted in the death of one patient happened after
Table 5 Published studies of a dose-intense regimen of capecitabine and oxaliplatin









_________ q2w Oxali 85 mg/m2
19 Cape 1750 mg/m2 BDd1-7 98% 131% 47.1% 6.9 31.6%
30 Cape 1500 mg/m2 BD d1-7 98% 113% 26.9% 8.9 23.3%
Bevac 5 mg/kg
Phase II trials
Scheithauer [11] 89 q2w Oxali 85 mg/m2 98% 131% 54.5% 10.5 9%
Cape 1750 mg/m2 BDd1-7
vs.
q3w Oxali 130 mg/m2 42.2% 6 12%
Cape 1000 mg/m2 BD d1-14
Fedele [19] 47** q2w Oxali 100 mg/m2 115% 75% 51% - 4.3%
Cape 1000 mg/m2BD d1-7
Yuan [20] 23** q2w Oxali 85 mg/m2 98% N/A 61% - 26%
Cape 2500 mg BD d1-7
Cetux 250 or 500 mg/m2
Lembersky [21] q2w Oxali 85 mg/m2 38% 10 18%
11*** Cape 1250 mg/m2BDd1-7 98% 94%
29 Cape 1500 mg/m2 BDd1-7 98% 113%
Bevac 5 mg/kg
Phase III trials
Hurwitz [17] 435 q2w Oxali 85 mg/m2 98% 113% 21.7% 8.4 29%
Cape 1500 mg/m2 BD d1-7
Bevac 5 mg/kg
vs.
q3w Oxali 130 mg/m2 29.4% 9.7 24%
Cape 850 mg/m2 BD d1-7
Bevac 5 mg/kg
Tournigand [22] 200 q2w Oxali 100 mg/m2 115% 94% - - 21%
Cape 1250 mg/m2BD d1-7 - -
Bevac 5 mg/kg
vs.
q2w Oxali 100 mg/m2 5%
LV 400 mg/m2
5FU 2400 mg/m2 ci 46 hrs
Bevac 5 mg/kg
Oxali: Oxaliplatin; Cape: Capecitabine; Bevac: Bevacizumab; LV: leucovorin; 5FU: 5-fluorouracil.
*Compared to standard CapeOx: oxaliplatin 130 mg/m2 on Day 1 and capecitabine 1000 mg/m2/BD D1-14.
**Number eligible for toxicity analysis.
***Dose of capecitabine was increased in trial due to tolerability at low dose.
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underlying DPD deficiency, and this death may not have
been attributable to the dose-intense schedule. One of
the deaths was from tumour site perforation that wasdeemed treatment-related. In the BEAT study, a phase 4
study of bevacizumab 5 mg/kg (biweekly regimens) or
7.5 mg/kg (3-weekly regimens) in combination with
FOLFOX, CapOx (18% of patients), FOLFIRI or 5-FU,
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with unresected colorectal cancers, indicating that this
is a rare event [18]. The rates of perforation in our study
were higher than seen in other studies. This may be ei-
ther a chance finding or due to an interaction with this
schedule. With these events our study could not dem-
onstrate safety of the dose-intense CapOx-Bev regimen.
The response rate in the C1750 group was similar to
other 5-FU-Oxaliplatin-Bevacizmab regimens and may
have been higher if confirmatory scans were completed
at 4 weeks instead of 8. The response rate was lower at
the reduced dose of capecitabine, however the study was
not powered to compare the response rate between dose
levels. The median PFS and OS of seen in our study are
similar to other reported regimens. Our data are similar
to the phase III trial published recently [17], with lower
response rates than in the initial phase II studies, suggest-
ing difficulty translating studies in more selected small
groups of patients to the more general phase 3 population,
even when performance status was relatively good. It is
also noted that the eligible patients did not have resectable
disease and were at the worse end of the spectrum for
metastatic/recurrent disease.
The cluster of adverse events, particularly perforation
and toxic death reminiscent of DPD deficiency may have
been due to chance occurrence or may have been due to
the toxicity of a dose intense regimen. A phase one design
with a smaller population may not have detected these
events, whereas a larger, randomised study may have bal-
anced events between arms (if the adverse events are due
to chance). These factors are limitations of a single-arm
phase 2 design study.
The primary endpoint of the study was safety and feasi-
bility as measured by the proportion of patients who re-
ceived at least 75% of the planned dose for the first two
cycles. Whilst this was achieved for 80% of participants,
the toxicity over the course of treatment was too great.
Despite preclinical modelling and two other studies of
similar dose-intense regimens showing possible enhanced
efficacy with acceptable toxicity, we could not demon-
strate this with our regimen. We conclude that dose
intense CapOx-Bev should not be used outside of clin-
ical studies.
Competing interests
Roche New Zealand provided a grant to support core funding to Cancer
Trials New Zealand separate to the funding of this study. MF is a Director of
CTNZ. CJ received travel assistance to attend an educational meeting from
Roche New Zealand. All remaining authors have declared no conflicts of
interest.Authors’ contributions
Conception and design: MF KS. Provision of study materials or patients: MF
KS PT AO BR DP JA RI VH. Collection and assembly of data: KS VH. Data
analysis and interpretation: MF KS VH SD CJ. Manuscript writing: CJ SD MF.
Final approval of manuscript: all authors.Acknowledgements





1Department of Medicine, University of Otago, Dunedin, New Zealand.
2Preventive and Social Medicine, University of Otago, Dunedin, New Zealand.
3Cancer Trials New Zealand, University of Auckland, Level 1, Building 505, 85
Park Road, Grafton, Auckland, New Zealand. 4Auckland City Hospital,
Auckland, New Zealand. 5Wellington Cancer Centre, Capital and Coast
Health, Wellington, New Zealand. 6Christchurch School of Medicine,
University of Otago, Christchurch, New Zealand. 7University of Otago,
Dunedin, New Zealand. 8Lyell McEwin Hospital, Elizabeth Vales, South
Australia, Australia. 9Regional Cancer Treatment Service, MidCentral Health,
Palmerston North, New Zealand.
Received: 5 March 2013 Accepted: 23 September 2014
Published: 2 October 2014
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA: A Cancer Journal for Clinicians 2011, 61(2):69–90.
2. Jemal A, Center MM, DeSantis C, Ward EM: Global patterns of cancer
incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev
2010, 19:1893–1907.
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W,
Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R,
Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin
for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335–2342.
4. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S,
Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J: Bevacizumab
in combination with oxaliplatin-based chemotherapy as first-line therapy
in metastatic colorectal cancer: a randomized phase III study. Journal of
clinical oncology: official journal of the American Society of Clinical Oncology
2008, 26(12):2013–2019.
5. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S,
Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Saltz L: Randomized
phase III study of capecitabine plus oxaliplatin compared with
fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic
colorectal cancer. J Clin Oncol 2008, 26(12):2006–2012.
6. Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, Adenis A,
Faroux R, Rebischung C, Bergougnoux L, Kockler L, Douillard J-Y:
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin
plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic
colorectal cancer. Int J Cancer 2011, 128:682–690.
7. Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, Gollins S,
Siu LL, Laguerre S, Cunningham D: Capecitabine plus oxaliplatin (XELOX)
versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line
therapy in metastatic colorectal cancer: a randomized phase III
noninferiority study. Annals of oncology: official journal of the European
Society for Medical Oncology / ESMO 2008, 19(10):1720–1726.
8. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A,
Grossmann J, Sawada N, Schoffski P, Sobrero A, Van Cutsem E, Diaz-Rubio E:
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with
metastatic colorectal cancer. Journal of clinical oncology: official journal of the
American Society of Clinical Oncology 2004, 22(11):2084–2091.
9. Norton L, Dugan U, Young D, Farrell C, Tanaka Y, Theodoulou M, Traina T, Hudis
C: Optimizing chemotherapeutic dose-schedule (CDS) by Norton-Simon
Modeling: Capecitabine (Xeloda(R)= X). AACR Meeting Abstracts 2005,
2005(1):1182-d.
10. Scheithauer W, Kornek GV, Raderer M, Schull B, Schmid K, Langle F,
Huber H: Intermittent weekly high-dose capecitabine in combination
with oxaliplatin: a phase I/II study in first-line treatment of patients with
advanced colorectal cancer. Ann Oncol 2002, 13:1583–1589.
11. Scheithauer W, Kornek GV, Raderer M, Schull B, Schmid K, Kovats E,
Schneeweiss B, Lang F, Lenauer A, Depisch D: Randomized multicenter
phase II trial of two different schedules of capecitabine plus oxaliplatin
as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003,
21:1307–1312.
Jackson et al. BMC Cancer 2014, 14:737 Page 8 of 8
http://www.biomedcentral.com/1471-2407/14/73712. Kaplan ELMP: Nonparametric estimation from incomplete observations.
J Am Stat Assoc 1958, 53:457–481.
13. Brookmeyer RCJ: A confidence interval for the median survival time.
Biometrics 1982, 38:29–41.
14. Traina TA, Theodoulou M, Feigin K, Patil S, Tan KL, Edwards C, Dugan U,
Norton L, Hudis C: Phase I study of a novel capecitabine schedule based
on the Norton-Simon mathematical model in patients with metastatic
breast cancer. J Clin Oncol 2008, 26:1797–1802.
15. Gajria D, Feigin K, Tan LK, Patil S, Geneus S, Theodoulou M, Norton L,
Hudis CA, Traina TA: Phase 2 trial of a novel capecitabine dosing
schedule in combination with bevacizumab for patients with metastatic
breast cancer. Cancer 2011, 117:4125–4131.
16. Hochster HS, Hart LL, Ramanathan RK, Hainsworth JD, Griffing S, Mass RD,
Nagarwala Y, Jirau-Lucca G, Shpilsky A, Childs BH: Safety and efficacy of
oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line
treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-
Study [abstract no. 3510], Presented at the 42nd Annual Meeting of the
American Society of Clinical Oncology. Atlanta (GA): 2006 Jun 2–6.
17. Hurwitz H, Patt YZ, Henry D, Garbo L, Mitchell EP, Kohles J, Spigel D: Phase
III study of standard triweekly versus dose-dense biweekly capecitabine
(C) + Oxaliplatin (O) + Bevacizumab (B) as first-line treatment for
metastatic colorectal cancer (mCRC): XELOX-a-DVS (dense versus
standard): interim analysis. ASCO Meeting Abstracts 2009, 27:4078.
18. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M,
Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D,
First BEAT investigators: Safety and efficacy of first-line bevacizumab with
FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal
cancer: the BEAT study. Ann Oncol 2009, 20(11):1842–1847.
19. Fedele P, Di Maggio G, Leo S, Nanni F, Giuliani F, Biglietto M, Lorusso V,
Cinieri S, Colucci G, Maiello E: Bi-weekly administration of capecitabine +
oxaliplatin (Xelox-2) in first-line treatment of advanced colorectal cancer
(ACRC): A phase II study of the Gruppo Oncologico dell'Italia Meridionale
(GOIM). J Clin Oncol 2009, 27(suppl):abstr e15066.
20. Yuan Y, Ma H, Cohen D, Ryan T, Choi H, Love E, Awad M, Khambata-Ford S,
Mauro D, Hochster H: Activity and tolerance of biweekly CapeOx-
cetuximab in 1st line therapy of metastatic colorectal cancer (mCRC):
Relation to K-ras mutation status. J Clin Oncol 2009, 27(suppl):abstr e15018.
21. Lembersky B, Sehgal R, Rajasenan K, Crandall T, Balaban E, Pinkerton A, Kane
P, Potter D, Kinney C, Ramanathan RK: Phase II study of bevacizumab
(BEV), weekly (wkly) intermittent capecitabine (Cap), and oxaliplatin (Ox)
on an every-2-week schedule for patients (Pts) with untreated advanced
colorectal cancer (CRC). J Clin Oncol 2008, 26(suppl):abstr 4061.
22. Tournigand C, Lledo G, Delord J, André T, Maindrault-Goebel F, Louvet C,
Scheithauer W, de Gramont A: Modified (m)Folfox7/bevacizumab (B) or
modified (m)Xelox/bevacizumab with or without erlotinib (E) in first-line
metastatic colorectal cancer (MCRC): Results of the feasibility phase
of the DREAM-OPTIMOX3 study (GERCOR). J Clin Oncol 2007,
25(18S):suppl; abstr 4097.
doi:10.1186/1471-2407-14-737
Cite this article as: Jackson et al.: Dose-intense capecitabine, oxaliplatin
and bevacizumab as first line treatment for metastatic, unresectable
colorectal cancer: a multi-centre phase II study. BMC Cancer 2014 14:737.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
